Alpha(v) beta (6) integrin (avb6) binding polypeptides are disclosed herein, and their use in treating and detecting tumors, and their use in treating pulmonary fibrosis.

Alpha(v) beta (6) integrin (avb6) binding polypeptides are disclosed herein, and their use in treating and detecting tumors, and their use in treating pulmonary fibrosis.

The invention relates to programmed death-ligand 1 (PD-L1) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of producing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods for enhancing or reducing or inhibiting an immune response in a mammal.

The invention relates to programmed death-ligand 1 (PD-L1) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of producing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods for enhancing or reducing or inhibiting an immune response in a mammal.

The present application provides fusion proteins that have a TGFβ superfamily receptor ectodomain (such as fusion proteins that have a TGFβ superfamily receptor ectodomain and bind to PD-L1), nucleic acids encoding the fusion protein or a portion thereof, vectors comprising the nucleic acids, host cells containing the vectors, methods of preparing the fusion proteins, pharmaceutical compositions comprising any of the fusion proteins, and methods of using the fusion proteins or compositions.

A composition of renaturation buffer solution for dimeric proteins and method for using it. The renaturation buffer solution comprises buffer, oxido shuffling system, primary additives, chelating agent and polysorbate compound. The method for renaturation of dimeric proteins includes solubilization of target proteins using a solubilization buffer, solution dilution of the renatured target protein using a renaturation buffer containing polysorbate compound(s), concentrating of the target protein solution to a concentration approaching saturation. A method of applying renature denatured or misfolded proteins to become correctly folded and bioactive. A method of proper renaturation of recombinant proteins that have been expressed using translation vehicles (e.g., bacteria, insects, etc.) and proteins damaged by mechanical shearing, chemical stresses, and other stresses.

A composition of renaturation buffer solution for dimeric proteins and method for using it. The renaturation buffer solution comprises buffer, oxido shuffling system, primary additives, chelating agent and polysorbate compound. The method for renaturation of dimeric proteins includes solubilization of target proteins using a solubilization buffer, solution dilution of the renatured target protein using a renaturation buffer containing polysorbate compound(s), concentrating of the target protein solution to a concentration approaching saturation. A method of applying renature denatured or misfolded proteins to become correctly folded and bioactive. A method of proper renaturation of recombinant proteins that have been expressed using translation vehicles (e.g., bacteria, insects, etc.) and proteins damaged by mechanical shearing, chemical stresses, and other stresses.

In part, the present disclosure relates methods for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or one or more complications of a myeloproliferative disorder. The present disclosure further relates methods for treating, preventing, or reducing the severity of a Janus kinase-associated disorder or one or more complications of a Janus kinase-associated disorder. In certain aspects the disclosure provides TβRII antagonists for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or a Janus kinase-associated disorder or one or more complications of a myeloproliferative disorder or a Janus kinase-associated disorder.

In part, the present disclosure relates methods for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or one or more complications of a myeloproliferative disorder. The present disclosure further relates methods for treating, preventing, or reducing the severity of a Janus kinase-associated disorder or one or more complications of a Janus kinase-associated disorder. In certain aspects the disclosure provides TβRII antagonists for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or a Janus kinase-associated disorder or one or more complications of a myeloproliferative disorder or a Janus kinase-associated disorder.

The invention provides a polynucleotide including at least one of (a) a sequence encoding a fusion protein including an antigen-presenting MHC molecule capable of being presented extramembranously of an extracellular vesicle; (b) a sequence encoding a fusion protein including a T cell stimulating cytokine or a subunit thereof capable of being presented extramembranously of an extracellular vesicle; (c) a sequence encoding a fusion protein including a T cell co-stimulatory molecule capable of being presented extramembranously of an extracellular vesicle; (d) a sequence encoding a fusion protein including an antigen-presenting MHC molecule and a T cell stimulating cytokine or a subunit thereof capable of being presented extramembranously of an extracellular vesicle; and (e) a sequence encoding a fusion protein including an antigen-presenting MHC molecule, a T cell stimulating cytokine or a subunit thereof, and a T cell co-stimulatory molecule capable of being presented extramembranously of an extracellular vesicle.